SynthesisJournal of thrombosis and haemostasis : JTH2026
Acquired hemophilia A following SARS-CoV-2 infection and vaccination: clinical summary and insights.
Synthesis in Journal of thrombosis and haemostasis : JTH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term impact of COVID-19 on haemophilia: a multicenter study in Southwest China.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcquired hemophilia A (AHA) is a bleeding diathesis caused by antifactor (F)VIII antibodies produced spontaneously or in response to triggers such as infections, autoimmune disorders, and malignancies. Recently, SARS-CoV-2 exposure, through both infection and vaccination, has emerged as a potential trigger.
objectivesThis is the first systematic review to compare cases of AHA following both SARS-CoV-2 infection and vaccination, presented alongside an illustrative case of severe AHA following SARS-CoV-2 infection during the Omicron variant outbreak. This is also the first study to explore the potential for molecular mimicry between SARS-CoV-2 spike protein (S) and human FVIII.
methodsA systematic review of AHA cases associated with SARS-CoV-2 infection (n = 14) or vaccination (n = 28) was conducted. An in silico analysis was performed to compare surface epitopes between SARS-CoV-2 S and human FVIII.
resultsAHA following SARS-CoV-2 infection or vaccination presented in individuals aged >60 years, with a significantly more rapid onset and potentially milder anti-FVIII response following vaccination. Spontaneous hemorrhagic shock was observed exclusively in AHA following infection. In silico analysis revealed 2 shared surface epitopes between SARS-CoV-2 S and FVIII, one of which is specific to the Omicron variant.
conclusionAHA following SARS-CoV-2 exposure is an emerging trend that may become more prominent with newer variants, highlighting the need for improved clinical characterization and earlier intervention. Preliminary evidence of shared surface epitopes between FVIII and SARS-CoV-2 S supports further investigation of molecular mimicry, and the identification of variant-specific epitopes offers insights into possible differences in immunogenicity between variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.